China Drug Approval Could Be A Game Changer For HBM Holdings (SEHK:2142)

What happened: China's National Medical Products Administration approved batoclimab SC for adult generalized myasthenia gravis patients who are anti acetylcholine receptor antibody positive, Harbour BioMed reported. Key numbers: In the Phase 3 trial, 58.2% of treated participants met the primary MG ADL response endpoint Why it matters: The approval gives HBM Holdings a commercial stage subcutaneous biologic and a new potential product revenue source, though the content notes the immediate financial impact is still uncertain and adds commercial and post approval study spend to the pipeline.

China's National Medical Products Administration approved batoclimab SC for adult generalized myasthenia gravis patients who are anti acetylcholine receptor antibody positive, Harbour BioMed reported.

The approval gives HBM Holdings a commercial stage subcutaneous biologic and a new potential product revenue source, though the content notes the immediate financial impact is still uncertain and adds commercial and post approval study spend to the pipeline.